- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02292758
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To assess and compare the progression-free survival (PFS) of patients receiving irinotecan, cetuximab, and bevacizumab with patients receiving irinotecan, cetuximab and placebo, in the population of patients with RAS wild-type, irinotecan-refractory metastatic colorectal cancer (mCRC) who also previously received bevacizumab in at least one prior line therapy.
SECONDARY OBJECTIVES:
I. To assess the adverse event (AE) profile and safety of the proposed treatment in this population.
II. To assess and compare the overall survival (OS) between treatment arms in this population.
III. To assess and compare the disease control rate (DCR) between treatment arms in this population.
IV. To assess and compare the overall response rate (ORR) between treatment arms in this population.
V. To assess and compare the duration of response between treatment arms in this population.
VI. To assess and compare time to treatment failure between treatment arms in this population.
VII. To assess relative dose intensity of treatment agents between treatment arms in this population.
CORRELATIVE OBJECTIVES:
I. Determine the change in genotype concentrations of prespecified gene mutations in circulating cell-free deoxyribonucleic acid (DNA) (cfDNA) collected serially during protocol treatment.
II. Explore the predictive value of pretreatment mutation status, germline single nucleotide polymorphisms (SNPs), and gene expression signatures for cetuximab sensitivity and resistance.
III. Explore the predictive value of dynamic changes in mutation status and gene expression signatures for cetuximab sensitivity and resistance.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive cetuximab intravenously (IV) over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for up to 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic in Arizona
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Saint Luke's Mountain States Tumor Institute
-
-
Iowa
-
Sioux City, Iowa, United States, 51101
- Siouxland Regional Cancer Center
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas - Wichita
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center Jefferson
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Michigan Cancer Research Consortium NCORP
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Joseph, Missouri, United States, 64507
- Heartland Regional Medical Center
-
Saint Louis, Missouri, United States, 63131
- Missouri Baptist Medical Center
-
-
New Hampshire
-
Hooksett, New Hampshire, United States, 03106
- New Hampshire Oncology Hematology PA-Hooksett
-
-
New York
-
Syracuse, New York, United States, 13210
- State University of New York Upstate Medical University
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54301
- Saint Vincent Regional Cancer Center CCOP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Metastatic or locally advanced (unresectable) colorectal cancer with histological confirmation of adenocarcinoma
- Measurable disease
- RAS wild-type tumor; Note: evidence of EGFR expression in the tumor is not required
- Previous failure of at least one fluoropyrimidine- and irinotecan-containing chemotherapy regimen for metastatic disease; Note: previous failure is defined as disease progression while receiving treatment or within 6 weeks after the last dose of irinotecan; failure for this assessment is defined as any enlargement of measurable or assessable lesion(s) or the development of any new lesion; a rising tumor marker alone is not sufficient to define failure; patients can have received irinotecan in any previous line of therapy
- Treatment with bevacizumab in at least one prior line of therapy for metastatic disease
- Negative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0 or 1
- Total serum bilirubin =< institutional upper limit of normal (ULN) obtained =<14 days prior to randomization
- Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =<14 days prior to randomization
- Platelet count >= 100,000/mm^3 obtained =<14 days prior to randomization
- Hemoglobin >= 9.0 g/dL (hemoglobin may be supported by transfusion) obtained =<14 days prior to randomization
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) obtained =<14 days prior to randomization
- Creatinine within institutional limits of normal OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal obtained =<14 days prior to randomization
Urinary protein =< 1+ obtained =<14 days prior to randomization
- Patients discovered to have >= 2+ proteinuria must have a spot urine protein:creatinine ratio (UPCR) < 1.0
Partial thromboplastin time (PTT) =< 1 x institutional ULN and international normalized ratio (INR) =< 1.5 , unless participant is on full dose anticoagulation therapy obtained =<14 days prior to randomization; patients on full-dose anticoagulation are eligible if the following criteria are met:
- Patient has an in-range INR (usually 2-3) on a stable dose of warfarin or other anticoagulant =< 14 days or is on a stable dose of low molecular weight heparin
- Patient has no active bleeding or pathological condition that carries a high risk of bleeding (i.e., tumor involving major vessels or known varices)
- Patients receiving anti-platelet agents are eligible; in addition, patients who are on daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligible
- Life expectancy > 3 months
- Provide informed written consent
- Willing to provide blood samples for mandatory correlative and research purposes
- Willing to provide tissue and blood samples for mandatory banking purposes
- Any major surgery or open biopsy completed >= 4 weeks prior to randomization
- Any minor surgery or core biopsy completed >= 1 week prior to randomization and patient must have fully recovered from the procedure; Note: insertion of a vascular access device is not considered major or minor surgery
Exclusion Criteria:
- Presence of a RAS mutation in exons 2, 3, or 4 of KRAS or NRAS (patients with mutations in exons 2, 3, or 4 of KRAS and/or NRAS are excluded)
- Prior treatment with cetuximab or panitumumab
- Prior intolerance to irinotecan and/or bevacizumab despite dose reduction
- Known or suspected brain or central nervous system (CNS) metastases, or carcinomatous meningitis
- Active, uncontrolled infection, including hepatitis B, hepatitis C
- Concurrent anti-cancer therapy, including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocol
- Anti-cancer therapy =< 14 days prior to randomization
- Prior radiotherapy to > 25% of bone marrow; Note: standard rectal cancer chemoradiation will not exclude subject from study protocol
- Radiation therapy =< 2 weeks prior to randomization
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Co-morbid systemic illnesses or other severe concurrent disease, history of any psychiatric or addictive disorder, or laboratory abnormality, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Patients known to be human immunodeficiency virus (HIV) positive
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic pulmonary fibrosis or interstitial pneumonitis, or psychiatric illness/social situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, or may interfere with the conduct of the study or the interpretation of the study results
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanoma skin cancer, prostatic intraepithelial neoplasia without evidence of prostate cancer, lobular carcinoma in situ in one breast, or carcinoma-in-situ of the cervix that has been treated
- History of prior malignancy for which patient is receiving other specific treatment for their cancer
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, cetuximab, and/or bevacizumab that led to discontinuation of those agents
- Significant history of bleeding events or pre-existing bleeding diathesis =< 6 months of randomization (unless the source of bleeding has been resected)
- History of gastrointestinal perforation =< 12 months prior to randomization
- Predisposing colonic or small bowel disorders in which the symptoms are uncontrolled as indicated by baseline pattern of > 3 loose stools daily in subjects without a colostomy or ileostomy; subjects with a colostomy or ileostomy may be entered at investigator discretion
- Arterial thrombotic events =< 6 months prior to randomization; Note: this includes transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI)
- Clinically significant peripheral artery disease (e.g., claudication with < 1 block) or any other arterial thrombotic event
- Serious or non-healing wound, ulcer, or bone fracture
- History of hypertension not well-controlled (>= 160/90) even though on a regimen of anti-hypertensive therapy
- Evidence of Gilbert?s syndrome or known homozygosity for the UGT1A1*28 allele (special screening not required)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (cetuximab, bevacizumab, irinotecan)
Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1.
Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Given IV
Given IV
Other Names:
|
Active Comparator: Arm II (cetuximab, placebo, irinotecan)
Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1.
Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months
|
The distribution of PFS by group will be estimated using the method of Kaplan-Meier.
Median by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves.
The hazard ratio (HR) with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.
Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
PD: Any new lesion or increase by ≥50% of previously involved sites from nadir).
|
From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months
|
6-month and 12-month Progression-free Survival (PFS) Rates
Time Frame: From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months
|
The distribution of PFS by group will be estimated using the method of Kaplan-Meier.
Six and 12 month PFS rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves.
The hazard ratio (HR) with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.
Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
PD: Any new lesion or increase by ≥50% of previously involved sites from nadir).
|
From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: From the date of first tumor assessment with the response status being CR or PR to the date of 1st documented progressive disease, assessed up to 12 months
|
The distribution of DOR by treatment group will be estimated using the method of Kaplan-Meier.
Six and 12 month durable response (i.e.
maintaining CR or PR without progressive disease [PD]) rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves.
The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir
|
From the date of first tumor assessment with the response status being CR or PR to the date of 1st documented progressive disease, assessed up to 12 months
|
Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events
Time Frame: Up to 30 days from last dose of study treatment
|
The number of participants who experienced at least one grade 3 or higher adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
|
Up to 30 days from last dose of study treatment
|
Overall Survival (OS)
Time Frame: From randomization to the date of death due to any cause, assessed up to 24 months
|
The distribution of OS by group will be estimated using the method of Kaplan-Meier.
Median OS by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves.
The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.
|
From randomization to the date of death due to any cause, assessed up to 24 months
|
12-month, 18-month, and 24-month Overall Survival (OS) Rates
Time Frame: From randomization to the date of death due to any cause, assessed up to 24 months
|
The distribution of OS by group will be estimated using the method of Kaplan-Meier.
Twelve, 18- and 24-month survival rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves.
The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.
|
From randomization to the date of death due to any cause, assessed up to 24 months
|
Disease Control Rate (DCR)
Time Frame: Up to 2 years
|
Disease control is defined as maintaining Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) as the tumor assessment result during the defined time window.
DCR (percentage) is defined as number of patients with success of disease control divided by total number of patients in the analysis population multiplied by 100, excluding patients who refuse treatment before the initiation of any treatment.
CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir, SD: Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD
|
Up to 2 years
|
Overall Response Rate (ORR)
Time Frame: Up to 2 years
|
The response rate (percentage) is the percent of participants whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria.
Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients.
Response rates (including complete and partial response) will be tested using Fisher's exact test.
CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites
|
Up to 2 years
|
Percentage of Participants With Treatment Failure at 6 Months
Time Frame: assessed at 6 months
|
TTF is defined as the time from the date of randomization to the date of treatment discontinuation due to PD, death, or severe AE.
The distribution of TTF by treatment group will be estimated using the method of Kaplan-Meier.
Six month event-free rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves.
The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.
PD: Any new lesion or increase by ≥50% of previously involved sites from nadir
|
assessed at 6 months
|
Relative Dose Intensity (RDI)
Time Frame: Up to 2 years
|
RDI is defined as the total dose of protocol therapy a patient actually received (i.e., summation of actually received dose at each cycle) divided by the total planned dose (i.e., summation of planned dose level at each cycle) multiplied by 100.
Separate RDIs will be calculated for irinotecan and cetuximab.
Agent-specific RDI will be summarized by medians, and min and max values, all of which will be compared between the two treatment groups by the Wilcoxon Rank sum test.
|
Up to 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Genotype Concentrations of Prespecified Gene Mutations in Circulating Cell-free Deoxyribonucleic Acid (DNA) (cfDNA)
Time Frame: Baseline up to 2 years
|
The mean and median change in mutation concentration for each prespecified gene, and provide the corresponding 95% confidence intervals will be estimated.
Cox proportional hazards models will be applied to explore the predictive value of pretreatment mutation status for cetuximab sensitivity and resistance, using PFS and OS as the outcome variables.
|
Baseline up to 2 years
|
Dynamic Change in Mutation Concentration While the Patient is Receiving Cetuximab Treatment
Time Frame: Baseline up to 2 years
|
Scatter plots and box plots will be used to illustrate such change.
|
Baseline up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kimmie Ng, Academic and Community Cancer Research United
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Topoisomerase I Inhibitors
- Antibodies
- Immunoglobulins
- Bevacizumab
- Irinotecan
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Cetuximab
- Immunoglobulin G
- Endothelial Growth Factors
Other Study ID Numbers
- RU021302I (Other Identifier: Academic and Community Cancer Research United)
- P30CA015083 (U.S. NIH Grant/Contract)
- NCI-2016-02063 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Colorectal Cancer AJCC v7
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein ProficientUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedLower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
National Cancer Institute (NCI)Active, not recruitingStage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer AJCC v7 | Stage III Liver Cancer | Stage IV Liver Cancer | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Cholangiocarcinoma | Metastatic... and other conditionsUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPancreatic Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Malignant Neoplasm | Recurrent Colorectal Carcinoma | Pancreatic Neuroendocrine Carcinoma | Malignant Head and Neck Neoplasm | Stage III Nasopharyngeal Carcinoma... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | BRAF NP_004324.2:p.V600X | KRAS wt AlleleUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States